Cocrystal Pharma (NASDAQ:COCP – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.02), FiscalAI reports. The firm had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.10 million.
Cocrystal Pharma Stock Performance
Shares of COCP stock opened at $0.98 on Monday. The stock’s 50 day simple moving average is $1.08 and its 200 day simple moving average is $1.10. The company has a market capitalization of $18.88 million, a price-to-earnings ratio of -1.29 and a beta of 1.60. Cocrystal Pharma has a twelve month low of $0.76 and a twelve month high of $2.03.
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on the stock. Weiss Ratings downgraded shares of Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. HC Wainwright reissued a “buy” rating on shares of Cocrystal Pharma in a report on Friday, October 9th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold”.
Cocrystal Pharma Company Profile
Cocrystal Pharma, Inc. is a biotechnology company focused on discovering and developing antiviral medicines. Its research targets viral proteins involved in replication, with the goal of developing treatments for infections including influenza, hepatitis C, norovirus and coronaviruses. The company uses structure-based drug discovery and computational methods to identify compounds that act on these viral targets. Its investigational programs have included candidates for influenza A and hepatitis C; these are research-stage medicines and are not approved treatments.
Featured Articles
- Five stocks we like better than Cocrystal Pharma
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
